Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT3-R agonist) and was mimicked by ondansetron (5-HT3-R antagonist) and by escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT neurons express GABAB receptors, we examined their putative involvement in controlling 5-HT release after 5-HT3-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in vHPC. The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotransmission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuron Activity Related to Short-Term Memory
Fuster, J. M., & Alexander, G. E. (1971) · Science · doi:10.1126/science.173.3997.652 · Cited by 2,085 · cited 2×
“Primate studies have revealed that the neurobiological substrate of working memory is the maintenance of patterns of persistent neuronal activity in the dorsolateral PFC (equivalent to the prelimbic mPFC in rodents) during mnemonic processes (Curtis and D'Esposito, 2003; Fuster and Alexander, 1971).”
Prefrontal cortex in the rat: Projections to subcortical autonomic, motor, and limbic centers
Gabbott, P. L. A., Warner, T. A., Jays, P. R. L., Salway, P., & Busby, S. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20738 · Cited by 1,227 · cited 2×
“Given their predominant location in superficial layers, we expected that 5-HT3-R blockade would have a moderate impact on the activity of midbrain-projecting pyramidal neurons, located in layers V-VI (Gabbott et al., 2005).”
Cortical interneurons that specialize in disinhibitory control
Pi, H.-J., Hangya, B., Kvitsiani, D., Sanders, J. I., Huang, Z. J., & Kepecs, A. (2013) · Nature · doi:10.1038/nature12676 · Cited by 1,136 · cited 1×
“…in non-PV, non-somatostatin GABAergic interneurons, located in upper cortical layers (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004), which include neurogliaform cells (Ol ah et al., 2009; Tam as et al., 2003) and VIP-expressing interneurons (Lee et al., 2013; Pi et al., 2013).”
DeFelipe, J., & Fariñas, I. (1992) · Progress in Neurobiology · doi:10.1016/0301-0082(92)90015-7 · Cited by 975 · cited 1×
“PV-positive neurons are a subpopulation of GABAergic cells comprising chandelier and large basket cells (DeFelipe, 1997) that tightly control neuronal activity via axo-somatic (basket cells) or axo-axonic (chandelier cells) synapses on deep layer pyramidal neurons (DeFelipe and Fari~nas, 1992).”
New insights into the classification and nomenclature of cortical GABAergic interneurons
DeFelipe, J., López-Cruz, P. L., Benavides-Piccione, R., Bielza, C., Larrañaga, P., Anderson, S., Burkhalter, A., Cauli, B., Fairén, A., Feldmeyer, D., et al. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3444 · Cited by 833
A disinhibitory circuit mediates motor integration in the somatosensory cortex
Lee, S., Kruglikov, I., Huang, Z. J., Fishell, G., & Rudy, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3544 · Cited by 758 · cited 1×
“…in non-PV, non-somatostatin GABAergic interneurons, located in upper cortical layers (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004), which include neurogliaform cells (Ol ah et al., 2009; Tam as et al., 2003) and VIP-expressing interneurons (Lee et al., 2013; Pi et al., 2013).”
A prefrontal cortex–brainstem neuronal projection that controls response to behavioural challenge
Warden, M. R., Selimbeyoglu, A., Mirzabekov, J. J., Lo, M., Thompson, K. R., Kim, S.-Y., Adhikari, A., Tye, K. M., Frank, L. M., & Deisseroth, K. (2012) · Nature · doi:10.1038/nature11617 · Cited by 645 · cited 2×
“…(http://creativecommons.org/licenses/by-nc-nd/4.0/). afferents from the medial prefrontal cortex (mPFC) tightly control serotonergic activity (Celada et al., 2001; Hajos et al., 1998; MartinRuiz et al., 2001) and play a major role in the response to behavioural challenges (Warden et al., 2012).”
InfluentialInterneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641
Lee, S., Hjerling-Leffler, J., Zagha, E., Fishell, G., & Rudy, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1869-10.2010 · Cited by 600
DeFelipe, J. (1997) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(97)10013-8 · Cited by 550
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · cited 9×
“Vortioxetine inhibits the serotonin (5-HT) transporter (SERT) and shows high in vitro affinity for several 5-HT receptors (5-HT-R), including 5- HT3, 5-HT1A, 5-HT1B and 5-HT7 (Mork et al., 2012; Sanchez et al., 2015).”
InfluentialSelf-citationCelada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · cited 4×
“Given the presence of an excitatory control of the mPFC on 5-HT neuronal activity (Celada et al., 2001; Hajos et al., 1998), it is likely that the actions of vortioxetine in mPFC may contribute to the rapid recovery of serotonergic cell firing observed after repeated vortioxetine treatment (B etry…”
InfluentialSelf-citationSantana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486 · cited 2×
“The PFC contains a high density of neurons expressing 5-HT1A-R (Santana et al., 2004), whose physiological activation inhibits pyramidal neuron activity (Amarg os-Bosch et al., 2004; Puig et al., 2005).”
Electrical synapses between Gaba-Releasing interneurons
Galarreta, M., & Hestrin, S. (2001) · Nature Reviews Neuroscience · doi:10.1038/35077566 · Cited by 434 · cited 2×
“On the other hand, 5-HT3-R may be present in GABAergic interneurons controlling pyramidal neuron activity via axo-somatic contacts (Freund, 2003; Marlin and Carter, 2014) and/ or in cortical networks of synaptically- and electrically-coupled interneurons (Galarreta and Hestrin, 2001; Tam as et al., 2003; Traub et al.,…”
Regulation of cortical microcircuits by unitary GABA-mediated volume transmission
Oláh, S., Füle, M., Komlósi, G., Varga, C., Báldi, R., Barzó, P., & Tamás, G. (2009) · Nature · doi:10.1038/nature08503 · Cited by 386
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370
Identified sources and targets of slow inhibition in the neocortex
Tamás, G., Simon, A. L., & Szabadics, J. (2003) · Science · doi:10.1126/science.1082053 · Cited by 359 · cited 4×
“…in non-PV, non-somatostatin GABAergic interneurons, located in upper cortical layers (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004), which include neurogliaform cells (Ol ah et al., 2009; Tam as et al., 2003) and VIP-expressing interneurons (Lee et al., 2013; Pi et al., 2013).”
InfluentialMørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271 · cited 5×
“Vortioxetine inhibits the serotonin (5-HT) transporter (SERT) and shows high in vitro affinity for several 5-HT receptors (5-HT-R), including 5- HT3, 5-HT1A, 5-HT1B and 5-HT7 (Mork et al., 2012; Sanchez et al., 2015).”
InfluentialSelf-citationFast synaptic subcortical control of hippocampal circuits
Varga, V., Losonczy, A., Zemelman, B. V., Borhegyi, Z., Nyiri, G., Domonkos, A., Hangya, B., Holderith, N., Magee, J. C., & Freund, T. F. (2009) · Science · doi:10.1126/science.1178307 · Cited by 248
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · cited 1×
“Vortioxetine (Lu AA21004) is an antidepressant with a clinical efficacy similar to venlafaxine (Alvarez et al., 2012).”
Self-citationPehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97 · cited 5×
“This is an open access article u (B etry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) and its administration to rodents increases very markedly the extracellular concentration of monoamines in forebrain (Pehrson et al., 2013) to an extent greater than that produced by selective…”
InfluentialSelf-citationBétry, C., Etiévant, A., Pehrson, A., Sánchez, C., & Haddjeri, N. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.002 · Cited by 59 · cited 3×
“This is an open access article u (B etry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) and its administration to rodents increases very markedly the extracellular concentration of monoamines in forebrain (Pehrson et al., 2013) to an extent greater than that produced by selective…”
Self-citation
Cited by
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…receptors (which has secondary faciliatory effects on DA transmission) (MacIsaac et al., 2014) and others, such as vortioxetine, have appreciable affinities for several other 5-HT receptors (Riga et al., 2016; Thase et al., 2016) – perhaps most notably, the 5-HT6 receptor (Karila et al., 2015)).”
BackgroundBarnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Central 5-HT receptors and their function; present and future
Sharp, T., & Barnes, N. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108155 · Cited by 231
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Metadata
- Authors
- Riga, M. S., Sánchez, C., Celada, P., & Artigas, F.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 108
- Pages
- 73-81
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2344129250
- Cited by
- 88
- References
- 23
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.